

RUNX1\_RUNX1T1\_FUSION\_HSC\_DN, TONKS\_TARGETS\_OF\_RUNX1\_RUNX1T1\_FUSION\_HSC\_DN

HUANG\_GATA2\_TARGETS\_UP, HUANG\_GATA2\_TARGETS\_UP  
 TAKEDA\_TARGETS\_OF\_NUP98\_HOXA9\_FUSION\_8D\_DN, TAKEDA\_TARGETS\_OF\_NUP98\_HOXA9\_FUSION\_8D\_DN  
 TAKEDA\_TARGETS\_OF\_NUP98\_HOXA9\_FUSION\_16D\_UP, TAKEDA\_TARGETS\_OF\_NUP98\_HOXA9\_FUSION\_16D\_UP  
 SMIRNOV\_CIRCULATING\_ENDOTHELIOCYTES\_IN\_CANCER\_UP, SMIRNOV\_CIRCULATING\_ENDOTHELIOCYTES\_IN\_CANCER\_UP  
 TAVOR\_CEBPA\_TARGETS\_UP, TAVOR\_CEBPA\_TARGETS\_UP  
 ROSS\_AML\_WITH\_MLL\_FUSIONS, ROSS\_AML\_WITH\_MLL\_FUSIONS  
 ZHENG\_FOXP3\_TARGETS\_IN\_THYMUS\_UP, ZHENG\_FOXP3\_TARGETS\_IN\_THYMUS\_UP  
 TAKEDA\_TARGETS\_OF\_NUP98\_HOXA9\_FUSION\_8D\_UP, TAKEDA\_TARGETS\_OF\_NUP98\_HOXA9\_FUSION\_8D\_UP  
 WIERENGA\_STAT5A\_TARGETS\_DN, WIERENGA\_STAT5A\_TARGETS\_DN  
 NAKAJIMA\_MAST\_CELL, NAKAJIMA\_MAST\_CELL  
 MIKKELSEN\_IPS\_LCP\_WITH\_H3K4ME3, MIKKELSEN\_IPS\_LCP\_WITH\_H3K4ME3  
 BOYLAN\_MULTIPLE\_MYELOMA\_D\_DN, BOYLAN\_MULTIPLE\_MYELOMA\_D\_DN  
 ZHANG\_ANTIVIRAL\_RESPONSE\_TO\_RIBAVIRIN\_DN, ZHANG\_ANTIVIRAL\_RESPONSE\_TO\_RIBAVIRIN\_DN  
 OKUMURA\_INFLAMMATORY\_RESPONSE\_LPS, OKUMURA\_INFLAMMATORY\_RESPONSE\_LPS  
 PID\_HDAC\_CLASSII\_PATHWAY, PID\_HDAC\_CLASSII\_PATHWAY  
 DAVICIONI\_TARGETS\_OF\_PAX\_FOXO1\_FUSIONS\_DN, DAVICIONI\_TARGETS\_OF\_PAX\_FOXO1\_FUSIONS\_DN  
 SHEDDEN\_LUNG\_CANCER\_GOOD\_SURVIVAL\_A4, SHEDDEN\_LUNG\_CANCER\_GOOD\_SURVIVAL\_A4  
 TONKS\_TARGETS\_OF\_RUNX1\_RUNX1T1\_FUSION GRANULOCYTE\_DN, TONKS\_TARGETS\_OF\_RUNX1\_RUNX1T1\_FUSION GRANULOCYTE\_DN  
 MARKEY\_RB1\_CHRONIC\_LOF\_DN, MARKEY\_RB1\_CHRONIC\_LOF\_DN  
 GRABARCZYK\_BCL11B\_TARGETS\_UP, GRABARCZYK\_BCL11B\_TARGETS\_UP  
 PID\_INTEGRIN\_CS\_PATHWAY, PID\_INTEGRIN\_CS\_PATHWAY  
 PARK\_TRETINOIN\_RESPONSE\_AND\_PML\_RARA\_FUSION, PARK\_TRETINOIN\_RESPONSE\_AND\_PML\_RARA\_FUSION  
 MORI\_PRE\_BI\_LYMPHOCYTE\_DN, MORI\_PRE\_BI\_LYMPHOCYTE\_DN  
 CERIBELLI\_GENES\_INACTIVE\_AND\_BOUND\_BY\_NFY, CERIBELLI\_GENES\_INACTIVE\_AND\_BOUND\_BY\_NFY  
 ENGELMANN\_CANCER\_PROGENITORS\_UP, ENGELMANN\_CANCER\_PROGENITORS\_UP  
 REACTOME\_GPVI\_MEDIATED\_ACTIVATION\_CASCADE, REACTOME\_GPVI\_MEDIATED\_ACTIVATION\_CASCADE  
 BOSCO\_ALLERGEN\_INDUCED\_TH2\_ASSOCIATED\_MODULE, BOSCO\_ALLERGEN\_INDUCED\_TH2\_ASSOCIATED\_MODULE  
 TONKS\_TARGETS\_OF\_RUNX1\_RUNX1T1\_FUSION\_ERYTHROCYTE\_DN, TONKS\_TARGETS\_OF\_RUNX1\_RUNX1T1\_FUSION\_ERYTHROCYTE\_DN  
 KEGG\_APOPTOSIS, KEGG\_APOPTOSIS  
 REACTOME\_CELL\_SURFACE\_INTERACTIONS\_AT\_THE\_VASCULAR\_WALL, REACTOME\_CELL\_SURFACE\_INTERACTIONS\_AT\_THE\_VASCULAR\_WALL  
 ACOSTA\_PROLIFERATION\_INDEPENDENT\_MYC\_TARGETS\_DN, ACOSTA\_PROLIFERATION\_INDEPENDENT\_MYC\_TARGETS\_DN  
 KLEIN\_PRIMARY\_EFFUSION\_LYMPHOMA\_DN, KLEIN\_PRIMARY\_EFFUSION\_LYMPHOMA\_DN  
 DEMAGALHAES\_AGING\_UP, DEMAGALHAES\_AGING\_UP  
 LENAOUR\_DENDRITIC\_CELL\_MATURATION\_UP, LENAOUR\_DENDRITIC\_CELL\_MATURATION\_UP  
 ROSS\_ACUTE\_MYELOID\_LEUKEMIA\_CBF, ROSS\_ACUTE\_MYELOID\_LEUKEMIA\_CBF  
 FAELT\_B\_CLL\_WITH\_VH\_REARRANGEMENTS\_UP, FAELT\_B\_CLL\_WITH\_VH\_REARRANGEMENTS\_UP  
 REACTOME\_NUCLEAR\_EVENTS\_KINASE\_AND\_TRANSCRIPTION\_FACTOR\_ACTIVATION, REACTOME\_NUCLEAR\_EVENTS\_KINASE\_AND\_TRANSCRIPTION\_FACTOR\_ACTIVATION  
 MAGRANGEAS\_MULTIPLE\_MYELOMA\_IGG\_VS\_IGA\_DN, MAGRANGEAS\_MULTIPLE\_MYELOMA\_IGG\_VS\_IGA\_DN  
 BASSO\_CD40\_SIGNALING\_UP, BASSO\_CD40\_SIGNALING\_UP  
 DAVICIONI\_PAX\_FOXO1\_SIGNATURE\_IN\_ARMS\_DN, DAVICIONI\_PAX\_FOXO1\_SIGNATURE\_IN\_ARMS\_DN  
 TAKEDA\_TARGETS\_OF\_NUP98\_HOXA9\_FUSION\_6HR\_DN, TAKEDA\_TARGETS\_OF\_NUP98\_HOXA9\_FUSION\_6HR\_DN  
 WANG\_IMMORTALIZED\_BY\_HOXA9\_AND\_MEIS1\_DN, WANG\_IMMORTALIZED\_BY\_HOXA9\_AND\_MEIS1\_DN  
 CROMER\_METASTASIS\_UP, CROMER\_METASTASIS\_UP  
 VALK\_AML\_CLUSTER\_13, VALK\_AML\_CLUSTER\_13  
 BYSTRYKH\_HEMATOPOIESIS\_STEM\_CELL\_SCP2\_QTL\_TRANS, BYSTRYKH\_HEMATOPOIESIS\_STEM\_CELL\_SCP2\_QTL\_TRANS  
 REACTOME\_METABOLISM\_OF\_ANGIOTENSINOGEN\_TO\_ANGIOTENSINS, REACTOME\_METABOLISM\_OF\_ANGIOTENSINOGEN\_TO\_ANGIOTENSINS  
 GAVIN\_IL2\_RESPONSIVE\_FOXP3\_TARGETS\_UP, GAVIN\_IL2\_RESPONSIVE\_FOXP3\_TARGETS\_UP  
 SHETH\_LIVER\_CANCER\_VS\_TXNIP\_LOSS\_PAM2, SHETH\_LIVER\_CANCER\_VS\_TXNIP\_LOSS\_PAM2  
 PID\_FCER1\_PATHWAY, PID\_FCER1\_PATHWAY  
 FOSTER\_TOLERANT\_MACROPHAGE\_UP, FOSTER\_TOLERANT\_MACROPHAGE\_UP  
 DELASERNA\_TARGETS\_OF\_MYOD\_AND\_SMARCA4, DELASERNA\_TARGETS\_OF\_MYOD\_AND\_SMARCA4